» Articles » PMID: 37435855

The Additive Value of CA19.9 Monitoring in a Pancreatic Cyst Surveillance Program

Abstract

Background: Surveillance of pancreatic cysts focuses on the detection of (mostly morphologic) features warranting surgery. European guidelines consider elevated CA19.9 as a relative indication for surgery. We aimed to evaluate the role of CA19.9 monitoring for early detection and management in a cyst surveillance population.

Methods: The PACYFIC-registry is a prospective collaboration that investigates the yield of pancreatic cyst surveillance performed at the discretion of the treating physician. We included participants for whom at least one serum CA19.9 value was determined by a minimum follow-up of 12 months.

Results: Of 1865 PACYFIC participants, 685 met the inclusion criteria for this study (mean age 67 years, SD 10; 61% female). During a median follow-up of 25 months (IQR 24, 1966 visits), 29 participants developed high-grade dysplasia (HGD) or pancreatic cancer. At baseline, CA19.9 ranged from 1 to 591 kU/L (median 10 kU/L [IQR 14]), and was elevated (≥37 kU/L) in 64 participants (9%). During 191 of 1966 visits (10%), an elevated CA19.9 was detected, and these visits more often led to an intensified follow-up (42%) than those without an elevated CA19.9 (27%; p < 0.001). An elevated CA19.9 was the sole reason for surgery in five participants with benign disease (10%). The baseline CA19.9 value was (as continuous or dichotomous variable at the 37 kU/L threshold) not independently associated with HGD or pancreatic cancer development, whilst a CA19.9 of ≥ 133 kU/L was (HR 3.8, 95% CI 1.1-13, p = 0.03).

Conclusions: In this pancreatic cyst surveillance cohort, CA19.9 monitoring caused substantial harm by shortening surveillance intervals (and performance of unnecessary surgery). The current CA19.9 cutoff was not predictive of HGD and pancreatic cancer, whereas a higher cutoff may decrease false-positive values. The role of CA19.9 monitoring should be critically appraised prior to implementation in surveillance programs and guidelines.

Citing Articles

Pancreatic Cancer: A Review of Risk Factors.

Grigorescu R, Husar-Sburlan I, Gheorghe C Life (Basel). 2024; 14(8).

PMID: 39202722 PMC: 11355429. DOI: 10.3390/life14080980.


Novel Insights into Postoperative Surveillance in Resected Pancreatic Cystic Neoplasms-A Review.

Balaban D, Coman L, Balaban M, Costache R, Jinga M Diagnostics (Basel). 2024; 14(10).

PMID: 38786354 PMC: 11119521. DOI: 10.3390/diagnostics14101056.


Aspects and outcomes of surveillance for individuals at high-risk of pancreatic cancer.

Bogdanski A, van Hooft J, Boekestijn B, Bonsing B, Wasser M, Klatte D Fam Cancer. 2024; 23(3):323-339.

PMID: 38619782 PMC: 11255004. DOI: 10.1007/s10689-024-00368-1.


Can our experience with surveillance for inherited pancreatic cancer help to identify early pancreatic cancer in the general population?.

Lohr J, Ohlund D, Soreskog E, Andersson E, Vujasinovic M, Zethraeus N Fam Cancer. 2024; 23(3):399-403.

PMID: 38441833 PMC: 11255073. DOI: 10.1007/s10689-024-00363-6.


Recent Advances and Future Challenges in Pancreatic Cancer Care: Early Detection, Liquid Biopsies, Precision Medicine and Artificial Intelligence.

Daamen L, Molenaar I, Groot V J Clin Med. 2023; 12(23).

PMID: 38068536 PMC: 10707510. DOI: 10.3390/jcm12237485.


References
1.
Marrelli D, Caruso S, Pedrazzani C, Neri A, Fernandes E, Marini M . CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions. Am J Surg. 2009; 198(3):333-9. DOI: 10.1016/j.amjsurg.2008.12.031. View

2.
Wundsam H, Rosch C, Kirchweger P, Fischer I, Weitzendorfer M, Rumpold H . Long-Term Quality of Life after Pancreatic Surgery for Intraductal Papillary Mucinous Neoplasm. Eur Surg Res. 2021; 62(2):80-87. DOI: 10.1159/000515459. View

3.
Kim S, Park B, Seo J, Choi J, Choi J, Lee C . Carbohydrate antigen 19-9 elevation without evidence of malignant or pancreatobiliary diseases. Sci Rep. 2020; 10(1):8820. PMC: 7264353. DOI: 10.1038/s41598-020-65720-8. View

4.
Levink I, Jaarsma S, Koopmann B, van Riet P, Overbeek K, Meziani J . The additive value of CA19.9 monitoring in a pancreatic cyst surveillance program. United European Gastroenterol J. 2023; 11(7):601-611. PMC: 10493362. DOI: 10.1002/ueg2.12422. View

5.
Siegel R, Miller K, Jemal A . Cancer statistics, 2020. CA Cancer J Clin. 2020; 70(1):7-30. DOI: 10.3322/caac.21590. View